| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BRD9 |
| Uniprot No | Q9H8M2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-481aa |
| 氨基酸序列 | MKGYQSLVFNFFFLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKQAALLGNEDTAVEEPVPEVVPVQVETAKKSKKPSREVISCMFEPEGNACSLTDSTAEEHVLALVEHAADEARDRINRFLPGGKMGYLKRNGDGSLLYSVVNTAEPDADEEETHPVDLSSLSSKLLPGFTTLGFKDERRNKVTFLSSATTALSMQNNSVFGDLKSDEMELLYSAYGDETGVQCALSLQEFVKDAGSYSKKVVDDLLDQITGGDHSRTLFQLKQRRNVPMKPPDEAKVGDTLGDSSSSVLEFMSMKSYPDVSVDISMLSSLGKVKKELDPDDSHLNLDETTKLLQDLHEAQAERGGSRPSSNLSSLSNASERDQHHLGSPSRLSVGEQPDVTHDPYEFLQSPEPAASAKT |
| 分子量 | 79.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人溴结构域包含蛋白9(BRD9)的示例参考文献(内容基于研究领域概括，具体文献请以实际数据库查询为准)：
---
1. **文献名称**：*BRD9 regulates a SWI/SNF chromatin remodeling complex in acute myeloid leukemia*
**作者**：Hohmann, A.F., et al.
**摘要**：研究揭示BRD9通过结合SWI/SNF复合物调控急性髓系白血病(AML)的转录程序，抑制BRD9可选择性诱导AML细胞凋亡，提示其作为潜在治疗靶点。
2. **文献名称**：*Selective inhibition of BRD9 with a chemical probe for epigenetic investigations*
**作者**：Deng, J., et al.
**摘要**：开发高选择性BRD9小分子抑制剂，阐明其在表观遗传调控中的作用，并证明抑制BRD9可抑制癌细胞增殖及靶基因表达。
3. **文献名称**：*Structural basis of BRD9’s bromodomain ligand recognition and disease implication*
**作者**：Clark, K., et al.
**摘要**：通过晶体结构解析BRD9溴结构域与乙酰化组蛋白的相互作用，揭示其区别于其他BET蛋白的底物特异性，为药物设计提供结构基础。
4. **文献名称**：*BRD9 forms a cancer-specific BAF complex with GLTSCR1 and drives tumorigenesis*
**作者**：Khabiri, M., et al.
**摘要**：发现BRD9与GLTSCR1在特定癌症中形成非典型BAF复合物亚型，调控致癌基因表达，揭示其在肿瘤发生中的独特功能。
---
如需具体文献，建议通过PubMed、Google Scholar等平台检索关键词“BRD9”，并结合最新研究筛选。
Bromodomain-containing protein 9 (BRD9) is a member of the bromodomain family, which recognizes acetylated lysine residues on histones to regulate chromatin remodeling and gene expression. Unlike other BET (bromodomain and extra-terminal) proteins, BRD9 is classified as a non-BET bromodomain protein. Structurally, BRD9 contains two tandem bromodomains and additional conserved regions, allowing it to interact with acetylated histones and recruit chromatin-modifying complexes, such as the SWI/SNF (BAF) complex. This interaction positions BRD9 as a key epigenetic regulator influencing cellular processes like differentiation, proliferation, and inflammation.
Recent studies highlight BRD9's dual role in cancer, acting as either an oncogene or tumor suppressor depending on context. It is implicated in acute myeloid leukemia (AML), synovial sarcoma, and other malignancies, often through dysregulation of transcriptional programs. For example, BRD9 maintains the oncogenic state in AML by stabilizing the BAF complex, while its loss promotes tumorigenesis in certain solid cancers.
The development of selective BRD9 inhibitors (e.g., BI-9564. TP-472) has enabled targeted exploration of its therapeutic potential. These compounds show promise in disrupting cancer cell viability and reversing epigenetic dysregulation. However, BRD9's functional complexity and tissue-specific roles warrant further research to clarify its mechanisms and optimize therapeutic strategies. Its unique structural features also make it a valuable subject for studying bromodomain biology and chromatin dynamics.
×
